Noesion Radarnoesion.ai
Release2026-09-23

Enveda raised a $311M Series E at a $2B valuation. Catalio Capital Management led the round. Iconiq and others also participated. The valuation doubled in 12 months. Enveda uses AI to discover drugs from plants and microbes. It is testing drugs for severe skin conditions. It is also testing a drug to maintain weight loss after stopping GLP-1s. No AI-discovered drug has yet gained FDA approval.

What changed

Enveda was valued at $1B 12 months ago.

What it unlocks

Advancing more nature-derived AI drugs into human clinical trials.

  • $311M Series E
  • $2B valuation
  • valuation doubled in 12 months

Sources

Send this to someone who needs it

Shares the story and its sources. Nothing about you.

What does this mean for your job?

This is the story as everyone gets it. Once a week we send you the version written for your role — what changed, why it matters for the work you actually do, and one thing to try. Free while we tune it.